We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis has been under pressure ever since the FDA approved Zolgensma in May, and news emerged in August that the company had included inaccurate data in the preclinical package it submitted to the agency.